# A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

> clinical trial · VERIFIED · 2026-06-25

Status: RECRUITING · Sponsor: Akero Therapeutics, Inc · Condition: NASH With Fibrosis

- Company: Akero Therapeutics, Inc
- Sector: pharma
- Primary source: https://clinicaltrials.gov/study/NCT06215716

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.